FRANKFURT (dpa-AFX) - The good run of Redcare Pharmacy shares continued on Friday with a high since December 2021. The shares were already the biggest MDax winner in 2023 and are among the better performers in the mid-cap index this year. On Friday, they rose by up to three percent to EUR 157.60 in early Xetra trading. So far this year, they have repeatedly struggled in the EUR 153 to 154 range.

On Friday, Kepler Cheuvreux, a previously pessimistic analyst firm, abandoned this stance by upgrading the share to "hold". This means that the circle of pessimists is getting smaller. Among the institutions covered by the dpa-AFX analyst, only UBS has a negative stance. Buy recommendations predominate, with price targets ranging from 175 to 202 euros. The highest target comes from Deutsche Bank. Their analyst wrote this week that the e-prescription offers practically infinite potential. Its introduction has been seen as a driver of the online pharmacy's share price for months./tih/jha/